Rain lashed against the panoramic windows of Amelia “Amy” Hawthorne’s 42nd-floor office, blurring the already fading twilight view of the Chicago skyline.  The wind howled a mournful song, mirroring the churning in her stomach.  Scattered across her mahogany desk were the remnants of a demolished turkey club sandwich, a half-empty mug of lukewarm coffee, and the quarterly reports that had been the source of her gnawing unease for the past week. Amy, the newly appointed Chief Operating Officer of Thornton-Bellshaw Pharmaceuticals, tapped a manicured nail against a particularly damning paragraph outlining the plummeting sales of their flagship cholesterol medication.  The sleek, minimalist design of her office, normally a source of pride, felt more like a gilded cage tonight. Below, the city lights shimmered and pulsed, a vibrant organism oblivious to the pressure cooker of a situation brewing within the steel and glass tower that housed Thornton-Bellshaw and its increasingly anxious COO.
